Get notified when SNGX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSoligenix halts Phase 3 trial of lead drug HyBryte for futility, explores M&A options
Filed April 28, 2026 · Period ending April 28, 2026 · ~1 min read
Key Changes
-
high
Independent Data Monitoring Committee recommended halting the Phase 3 FLASH2 trial of HyBryte (lead drug for cutaneous T-cell lymphoma) due to futility—the drug was unlikely to demonstrate efficacy.
Item 8.01 verify on EDGAR → -
high
Company is evaluating strategic alternatives including merger and acquisition opportunities and potentially pivoting to dusquetide for Behçet's Disease treatment.
Item 8.01 verify on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (CAG 10-K) is open in full — no account needed.
Partner
Trade SNGX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify